期刊
NATURE NANOTECHNOLOGY
卷 6, 期 10, 页码 645-650出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/NNANO.2011.153
关键词
-
资金
- Safeway Foundation
- Providence Portland Medical Foundation
- Oregon Nanoscience and Microtechnologies Institute
- National Science Foundation
- National Institutes of Health [R01CA107243, R21CA141278]
- Directorate For Engineering
- Div Of Electrical, Commun & Cyber Sys [1057565] Funding Source: National Science Foundation
Therapeutic cancer vaccination is an attractive strategy because it induces T cells of the immune system to recognize and kill tumour cells in cancer patients. However, it remains difficult to generate large numbers of T cells that can recognize the antigens on cancer cells using conventional vaccine carrier systems(1,2). Here we show that alpha-Al2O3 nanoparticles can act as an antigen carrier to reduce the amount of antigen required to activate T cells in vitro and in vivo. We found that alpha-Al2O3 nanoparticles delivered antigens to autophagosomes in dendritic cells, which then presented the antigens to T cells through autophagy. Immunization of mice with alpha-Al2O3 nanoparticles that are conjugated to either a model tumour antigen or autophagosomes derived from tumour cells resulted in tumour regression. These results suggest that alpha-Al2O3 nanoparticles may be a promising adjuvant in the development of therapeutic cancer vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据